| Liu, Ling |
NCT04845399: Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A |
|
|
| Completed | 3 | 101 | RoW | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc, Jiangsu Gensciences lnc. | Hemophilia A | 06/21 | 06/21 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT06529445: Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects |
|
|
| Completed | 1 | 84 | RoW | High Dose VC004 Capsules, Median Dose VC004 Capsules, Low Dose VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | 08/24 | 08/24 | | |
NCT06619951: A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects |
|
|
| Completed | 1 | 56 | RoW | VC004 and Itraconazole, VC004 and rifampicin | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced or Metastatic Solid Tumor | 10/24 | 10/24 | | |
NCT05219643: Effect of Nava on Weaning Outcome in Patients With Mechanical Ventilation |
|
|
| Recruiting | N/A | 130 | RoW | NAVA, PSV | Southeast University, China, First Affiliated Hospital of Wannan Medical College | ARDS | 12/24 | 02/25 | | |
| Liu, Lin |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-Oļ¼recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
